Skip to content
Find a Provider
Jozal Moore, M.D.

Jozal Moore, M.D.

Hematology & Oncology , Cancer

No ratings currently available, see text in Ratings section below for explanation.

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 275-5823
Fax (585) 273-1051

About Me

Dr. Moore is a native of upstate New York and is committed to providing the best available therapies and compassionate care to patients in this region. To accomplish this, she believes in honest communication to ensure that treatments are driven both by clinical expertise and each patients' individu...
Dr. Moore is a native of upstate New York and is committed to providing the best available therapies and compassionate care to patients in this region. To accomplish this, she believes in honest communication to ensure that treatments are driven both by clinical expertise and each patients' individual needs. Dr. Moore is involved in clinical research in myeloid malignancies, stem cell transplantation, and the bone marrow microenvironment, to help improve outcomes and bring better treatment options to patients with hematologic malignancies and other blood disorders.

Conditions I Treat:
- Acute Leukemias,
- Myelodysplastic Neoplasms
- Myeloproliferative Neoplasms
- Stem Cell Transplantation & Cellular Therapies

Faculty Appointments

Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2020 - 2023

Residency, Internal Medicine, Brown University Medical School. 2017 - 2020

Education

MD | University of Rochester School of Medicine/Dentistry (USA). 2017

Awards

John & Carol Bennett Research Award. 2022

Segel-Halterman Fellowship Award for Scholarship in Hematology. 2021 - 2022

Award for Exemplary Primary Care. 2020

Excellence in Teaching Award. 2019

University of Rochester School of Medicine Summer Research Fellowship. 2014

Dean's Merit Scholarship Award. 2013 - 2017

Publications

Journal Articles

Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.

Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L

Blood advances.. 2024 December 108 (23):6139-6147. Epub 1900 01 01.

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2024 October 17 :JCO2400321. Epub 10/17/2024.

How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia.

Moore JW, Torres N, Superdock M, Mendler JH, Loh KP

Current treatment options in oncology.. 2022 August 23 (8):1086-1103. Epub 06/10/2022.

Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia.

Pelcovits A, Moore J, Bakow B, Niroula R, Egan P, Reagan JL

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.. 2021 September 29 (9):5323-5327. Epub 03/04/2021.

False-positive heparin-PF4 latex immunoturbidimetric assay due to lupus anti-coagulant interference: a case report.

McRae HL, Moore JW, Ifthikharuddin JJ, Refaai MA

British journal of haematology.. 2021 July 194 (1):211-213. Epub 04/20/2021.

Azacitidine and Venetoclax in AML.

Moore JW, Pelcovits A, Reagan JL

The New England journal of medicine.. 2020 November 19383 (21):2088. Epub 1900 01 01.

Books

Ferri's Clinical Advisor (2020)

Chapter: Antiphospholipid antibody syndrome

Ferri's Clinical Advisor (2019)

Chapter: Antiphospholipid antibody syndrome

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.